PuSH - Publication Server of Helmholtz Zentrum München: RIPK1 kinase-dependent inflammation and cell death contribute to the pathogenesis of COPD.

Information

Clues to quality of journals

Open Access Policy of Helmholtz Association 2016

CC Licencences

Publication Metrics

Navigation

Home

Deutsch

EVA: Electronic Publishing

New EVA Application

Research

Advanced Search

Browse by ...

... HMGU-Authors/Consortia

... Organizational Structure

... Journal

... Publication Type

... Research Data

... Arbeitsgruppen

... Publication Year

Publication overview

Statistics

Statistics (last 5 years)

OA Publications

Publish

Submit Publication

Import publication from...

...EVA

Report missing publication

Highlights

Support & Contact

Contact persons

Help

Data protection

Helmholtz Open Science

JANE Journal Estimator

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

Van Eeckhoutte, H.P.* ; Donovan, C.* ; Kim, R.Y.* ; Conlon, T.M. ; Ansari, M. ; Khan, H.* ; Jayaraman, R.* ; Hansbro, N.G.* ; Dondelinger, Y.* ; Delanghe, T.* ; Beal, A.M.* ; Geddes, B.* ; Bertin, J.* ; Berghe, T.V.* ; De Volder, J.* ; Maes, T.* ; Vandenabeele, P.* ; Vanaudenaerde, B.M.* ; Deforce, D.* ; Škevin, S.* ; Van Nieuwerburgh, F.* ; Verhamme, F.M.* ; Joos, G.F.* ; Idrees, S.* ; Schiller, H. B. ; Yildirim, A.Ö. ; Faiz, A.* ; Bertrand, M.J.M.* ; Brusselle, G.G.* ; Hansbro, P.M.* ; Bracke, K.R.*

RIPK1 kinase-dependent inflammation and cell death contribute to the pathogenesis of COPD.

Eur. Respir. J. 61:2201506 (2022)

Postprint

DOI

PMC

	Open Access Green

Abstract
Metrics
Extra information

RATIONALE: Receptor-interacting protein kinase 1 (RIPK1) is a key mediator of regulated cell death (including apoptosis and necroptosis) and inflammation, both drivers of chronic obstructive pulmonary disease (COPD) pathogenesis. OBJECTIVE: We aimed to define the contribution of RIPK1 kinase-dependent cell death and inflammation in the pathogenesis of COPD. METHODS: We assessed RIPK1 expression in single-cell RNA-sequencing data from human and mouse lungs and validated RIPK1 levels in lung tissue of COPD patients via immunohistochemistry. Next, we assessed the consequences of genetic and pharmacological inhibition of RIPK1 kinase activity in experimental COPD, using Ripk1^S25D ^/S25D kinase deficient mice and the RIPK1 kinase inhibitor GSK'547. MEASUREMENTS AND MAIN RESULTS: RIPK1 expression increased in alveolar type I (AT1), AT2, ciliated and neuroendocrine cells in human COPD. RIPK1 protein levels were significantly increased in airway epithelium of COPD patients, compared to never smokers and smokers without airflow limitation. In mice, exposure to cigarette smoke (CS) increased Ripk1 expression similarly in AT2 cells, and further in alveolar macrophages and T cells. Genetic and/or pharmacological inhibition of RIPK1 kinase activity significantly attenuated airway inflammation upon acute and subacute CS-exposure, as well as airway remodeling, emphysema and apoptotic and necroptotic cell death upon chronic CS-exposure. Similarly, pharmacological RIPK1 kinase inhibition significantly attenuated elastase-induced emphysema and lung function decline. Finally, RNA-sequencing on lung tissue of CS-exposed mice revealed downregulation of cell death and inflammatory pathways upon pharmacological RIPK1 kinase inhibition. CONCLUSIONS: RIPK1 kinase inhibition is protective in experimental models of COPD and may represent a novel promising therapeutic approach.

Impact Factor

Scopus SNIP

Web of Science
Times Cited

Scopus
Cited By

Altmetric

33.795

0.000